Nancy joined Amring Pharmaceuticals in August 2022 as Vice President, Quality. She oversees quality assurance and regulatory compliance. She has more than 25 years of experience with quality in the pharmaceutical industry. Nancy came to Amring from CRISPR Therapeutics where she served as Vice President, Quality. Prior to that, she served as Audit Head for Novartis and Executive Director Quality for Sandoz.
Nancy holds a B.S. in Clinical Laboratory Science from Thomas Jefferson University and an M.S. in Clinical Chemistry from West Chester University.